MRI of the breast before and after primary systemic therapy correlates with histopathological outcome in patients with locally advanced breast cancer (LABC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 9704-9704
Author(s):  
V. I. Russu ◽  
B. Lex ◽  
T. Gilster ◽  
K. Pfaffenberger ◽  
H. Volkholz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Systemic Therapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Primary Systemic Therapy ◽  
Before And After

Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer

2016 ◽  
Vol 468 (6) ◽  
pp. 675-686 ◽  
Author(s):  
Tímea Tőkés ◽  
Anna-Mária Tőkés ◽  
Gyöngyvér Szentmártoni ◽  
Gergő Kiszner ◽  
Lilla Madaras ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Advanced Breast Cancer ◽  
Systemic Therapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Primary Systemic Therapy

MRI of the breast before and after primary systemic therapy correlates with histopathological tumor size in patients with locally advanced breast cancer (LABC)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 507-507
Author(s):  
V. Russu ◽  
B. Lex ◽  
M. Popovich ◽  
K. Pfaffenberger ◽  
H. Volkholz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Systemic Therapy ◽  
Locally Advanced Breast Cancer ◽  
Tumour Size ◽  
Locally Advanced ◽  
Tumour Response ◽  
Primary Systemic Therapy ◽  
Response To Chemotherapy ◽  
Before And After

507 Background: Primary systemic therapy (PST) is a widely accepted preoperative treatment for patients with locally advanced breast cancer (LABC). Different authors beside our study-group showed that MRI is a sensitive method in describing the remaining size of an invasive breast lesion after PST. The established methods for measuring the size of lesions and monitoring the tumour-response to chemotherapy are clinical palpation, mammography and ultrasound, but specificity of these methods is unsatisfactory. Our prospective data is to clarify the accuracy of MRI in monitoring the tumour-response to PST is presented. Methods: 207 female patients (range of age: 26a- 78a) with LABC (cT2 – cT4) were examined with dynamic contrast enhanced MRI after PST. 173 (84%) patients have had MRI examination before and after PST. 145 (70%) patients had a ductal-invasive, 48 (23%) patients a lobular-invasive carcinoma. 70 (34%) patients were treated with sequential anthracyclin- and taxan-based chemotherapy and 137(66%) with only anthracyclin based chemotherapy. 51% patients were premenopausal. 70% had an ER-positive tumour. The measure of tumour-response to PST was graded in partial response (PR: >50% of tumour reduction mm2), no change (NC: <50%) and complete response (CR: no evidence of residual tumour-cells). Results: Comparing tumour-size measured by MRI before and after PST 119 (69 %) of the patients had PR and 25 (14.5%) CR. The histological tumour- size after PST strongly correlated with the size measured by MRI r = 0,758 (pâ€1 0.001). Analyzing the tumour-types ductal-invasive carcinomas were significant (p<0.001) better to monitor than lobular-invasive types (r=0.824/r=0.210). Conclusions: preoperative MRI seems to be a helpful tool in estimating the efficacy of the tumour-response to chemotherapy and for the operative planning in the patients with LABC after PST, especially for ductal-invasive tumours. No significant financial relationships to disclose.

Epirubicin and cyclophosphamide (EC) followed by weekly paclitaxel with/without trastuzumab as primary systemic therapy in locally advanced breast cancer: Phase II study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11590-e11590
Author(s):  
A. Hirano ◽  
T. Shimizu ◽  
M. Kamimura ◽  
N. Goto ◽  
O. Watanabe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Systemic Therapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Weekly Paclitaxel ◽  
Type I ◽  
Her2 Positive ◽  
Primary Systemic Therapy

e11590 Background: Primary systemic therapy (PST) has become a standard therapy for locally advanced breast cancer (LABC). The aim of this study was to evaluate the activity and toxicity of EC (epirubicin/cyclophosphamide) followed by weekly paclitaxel with/without trastuzumab as PST in LABC. Methods: Primary endpoint was pathologic complete response (pCR) rate in the breast and axilla, and secondary endpoints were breast conserving rate and toxicities. Patients with histologically diagnosed invasive breast cancer by core needle biopsy of the T2–4 (>3 cm) or N1–3 were included in this study. Eligible patients were age >20 years, had a performance status of 0 to 1, and had adequate organ functions. It was determined that the expected rate of pCR in the trial was 25%, and the sample size was calculated using the Simon method, with a type I error of 5% and a study power of 80%. The target enrollment was estimated to be 40 evaluable patients. Treatment: Patients received epirubicin (100 mg/m2) and cyclophosphamide (600mg/m2 ) every 3 weeks for four cycles followed by paclitaxel (80 mg/m2 ) every week for 12 cycles. Trastuzumab (2mg/kg) was added to paclitaxel in HER2-positive patients. Results: Forty-three patients were enrolled into this study and 3 patients withdrew. pCR were observed in 8 patients and pCR rate was 20.0% (95% confidence interval, 7.6- 32.4). Twenty-four patients (60.0%) underwent breast conserving surgery. In particular, patients with HER2 positive tumor had significantly higher rate of pCR than the others (62.5% vs. 8.6%; p=0.0014). Grade 4 neutropenia was recorded in 27.5% of the patients, and febrile neutropenia occurred in 4 patients (10.0%). No heart failure was seen. Conclusions: EC followed by weekly paclitaxel with/without trastuzumab was an active and well-tolerated treatment for LABC. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document